Provider Bulletins & MSA Updates
- Provider Bulletin No 190- Post COVID Provider Survey – As we begin to transition back to our pre-COVID servicing model we would like to get some feedback regarding servicing. Post-COVID Provider Survey was sent
- Provider Bulletin No 191- Removal of Prior Authorization for Hepatitis C Treatment – Effective 4.1.2021 – product MAVYRET (glecaprevir/pibrentasvir) will no longer require clinical prior authorization when prescribed in accordance with Food and Drug Administration (FDA) approved labeling.
- Provider Bulletin No 192 – Updated MDHHS Guidelines for Assessing and testing for Hepatitis C in Pregnant women and Children – Please refer to the attached PHC Fact Sheet from MDHHS regarding testing